Study identifies those at high risk for developing pancreatic cancer
the ONA take:
According to new findings published in the journal Digestive and Liver Diseases, an international team of researchers has developed a profile of the patient who would be at highest risk for developing pancreatic lesions that are most likely to develop into cancer.
To determine which patients are at high risk, the researchers analyzed data from 1,126 patients diagnosed with pancreatic lesions.
Of those, 84 developed invasive pancreatic cancer. Results showed that all 84 patients had all or some of the following factors: a history of smoking, a history of obesity, jaundice, and steatorrhea.
Researchers also identified the following risk factors: a larger cyst size, cysts in the main pancreatic duct, and nodules on the cyst wall. The study showed that abdominal pain did not put patients at high risk.
The authors estimate that between 10 and 40% of people have these lesions, but the majority do not develop pancreatic cancer.
The findings may help assure concerned patients who have these lesions that they are not at high risk for developing pancreatic cancer.
Researchers developed a profile of the patient who would be at highest risk for developing pancreatic lesions.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|